Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: The impact of cost on first-line therapy
Version of Record online: 5 JUN 2002
Copyright © 2002 by the American College of Rheumatology
Arthritis Care & Research
Volume 47, Issue 3, pages 285–290, 15 June 2002
How to Cite
Erkan, D., Yazici, Y., Harrison, M. J. and Paget, S. A. (2002), Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: The impact of cost on first-line therapy. Arthritis & Rheumatism, 47: 285–290. doi: 10.1002/art.10456
- Issue online: 5 JUN 2002
- Version of Record online: 5 JUN 2002
- Manuscript Accepted: 8 AUG 2001
- Manuscript Received: 3 FEB 2001
- 3Arthritis therapies: where are we now? J Musculoskel Med 2000; 17 Suppl: 7–15..
- 6Arthritis Care Algorithm Steering Committee. 1995 national survey of US rheumatologists: beliefs and practices regarding therapy, referrals, managed care, guidelines and algorithms [abstract]. Arthritis Rheum 1996; 39 Suppl 9: S16., , ,
- 8A phase III trial of etanercept vs methotrexate (MTX) in early rheumatoid arthritis [abstract]. Arthritis Rheum 1999; 42 Suppl 9: S11., , , , , .
- 9Enbrel (etanercept) vs methotrexate (MTX) in early rheumatoid arthritis: two-year followup [abstract]. Arthritis Rheum 2000; 43 Suppl 9: S26., , , , , , et al.
- 11102-wk clinical and radiologic results from the ATTRACT trial: a 2-year, randomized, controlled, phase 3 trial of infliximab in patients with active RA despite MTX [abstract]. Arthritis Rheum 2000; 43 Suppl 9: S26., , , , , , et al.
- 13Celecoxib Long-term Arthritis Safety Study, et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000; 284: 1247–55., , , , , ,
- 152001 Drug topics red book. New Jersey: Medical Economics; 2001. p. 304, 493.
- 16Treatment of poor-prognosis early rheumatoid arthritis: a randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis Rheum 2000; 43: 1809–10., , , , , , et al.